Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-12-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: interventionrisktolerabilitypharmacokinetics andheart
  Phrases that lowered it: healthyparticipantsperiodopen labelkg
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 9.8% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 2.5% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 16 (lowers risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports marked serious: 75.3% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 2 (lowers risk) · Design
• Sponsor's past trials: 153 (lowers risk) · Sponsor's track record
• Maximum age: 50 (lowers risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants NCT04484337 · started 2020 · scored riskier than 4% of active trials completed
• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants NCT06033547 · started 2023 · scored riskier than 3% of active trials completed
• Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study NCT03639311 · started 2018 · scored riskier than 41% of active trials completed
• A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA NCT05601128 · started 2023 · scored riskier than 27% of active trials completed
• Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers NCT02478463 · started 2017 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.